Hervorgehobene Publikationen

Featured publications

WID epigenetic tests for women’s cancers

Barrett, Herzog et al. Nature Communications, 2022.
Barrett, Sundström, Jones et al. Genome Medicine, 2022.
Barrett, Jones, Evans, Herzog et al. International Journal of Cancer, 2023.
Herzog et al. npj Precision Oncology. 2023.

We assessed the potential of epigenetic footprints in cervical screening samples to detect and risk predict breast, ovarian, womb and cervical cancers. Our research has the potential to change the future of personalised preventive medicine.

Featured Publications

qPCR test for womb cancer detection

Evans, Reisel, Jones, Bajrami et al, Lancet Oncology, 2023
Herzog, Marin et al. Journal of Clinical Oncology, 2022.
Schreiberhuber et al, International Journal of Cancer, 2022.

The WID™-qEC test detects endometrial cancer using qPCR with high accuracy in a cervical smear or vagina swab. The test has been validated in women with abnormal vaginal bleeding.

Featured consensus statement

Personalized early detection and prevention of breast cancer: ENVISION consensus statement

Pashayan et al., 2019, Nature Reviews Clinical Oncology

The consensus statement by Pashayan et al. provides an insight into evidence-based personalised intervention strategies for breast cancer prevention.

Featured Publication

WID epigenetic clocks

Barrett et al., 2022, Genome Biology

We describe a new epigenetic clock that highly accurately predicts chronological age. We moreover describe the WID-relative epithelial age (WID-REA) which specifically captures ageing of epithelial cells, which line our organs. The WID-REA may be informative to monitor individual breast cancer risk.

Featured publication

Breast cancer prevention with antiprogestins and the WID-Breast29

Bartlett et al., 2022, Genome Medicine

We describe the potential for individualised breast cancer prevention and risk monitoring using antiprogestins and a novel type of epigenetic test, the WID-Breast29, Our findings may be particularly valuable for individuals at the highest risk, for instance BRCA mutation carriers.

Featured publications

Association between the cervicovaginal microbiome and risk of ovarian cancer

We found that ovarian cancer and its underlying risk factors (such as BRCA1 mutations) are significantly associated with alterations in the cervicovaginal microbiome. Nene et al., 2019, The Lancet Oncology

We then went on to assess whether the DNA methylation status of the cervix could predict the cervicovaginal microbiome and our findings strongly support the view that the epithelial epigenome plays an essential role in hosting specific microbial communities.  Nene et al., 2020, Clinical Epigenetics

Alle Publikationen

Evans I, Reisel D, Jones A, Bajrami A, Nijjar S, Solangon SA, Arora R, Redl E, Schreiberhuber L, Ishaq-Parveen I, Rothärmel J, Herzog C, Jurkovic D, Widschwendter M. Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK. Lancet Oncol. 2023 Dec;24(12):1375-1386. doi: 10.1016/S1470-2045(23)00466-7. PMID: 37944542.

Herzog C, Jones A, Evans I, Reisel D, Olaitan A, Doufekas K, MacDonald N, Rådestad AF, Gemzell-Danielsson K, Zikan M, Cibula D, Dostálek L, Paprotka T, Leimbach A, Schmitt M, Ryan A, Gentry-Maharaj A, Apostolidou S, Rosenthal AN, Menon U, Widschwendter M. Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial. Int J Cancer. (2023 Oct 20). doi: 10.1002/ijc.34757. PMID: 37861205.

Herzog C, Jones A, Evans I, Zikan M, Cibula D, Harbeck N, Colombo N, Rådestad AF, Gemzell-Danielsson K, Pashayan N, Widschwendter M. DNA methylation at quantitative trait loci (mQTLs) varies with cell type and nonheritable factors and may improve breast cancer risk assessment. NPJ Precis Oncol. (2023 Sep 27); 7(1):99. doi: 10.1038/s41698-023-00452-2. PMID: 37758816.

Moqri M, Herzog C, Poganik JR; Biomarkers of Aging Consortium; Justice J, Belsky DW, Higgins-Chen A, Moskalev A, Fuellen G, Cohen AA, Bautmans I, Widschwendter M, Ding J, Fleming A, Mannick J, Han JJ, Zhavoronkov A, Barzilai N, Kaeberlein M, Cummings S, Kennedy BK, Ferrucci L, Horvath S, Verdin E, Maier AB, Snyder MP, Sebastiano V, Gladyshev VN. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. (2023 Aug 31); 186(18):3758-3775. doi: 10.1016/j.cell.2023.08.003. PMID: 37657418.

Köbel M, Kang EY, Weir A, Rambau PF, Lee CH, Nelson GS, Ghatage P, Meagher NS, Riggan MJ, Alsop J, Anglesio MS, Beckmann MW, Bisinotto C, Boisen M, Boros J, Brand AH, Brooks-Wilson A, Carney ME, Coulson P, Courtney-Brooks M, Cushing-Haugen KL, Cybulski C, Deen S, El-Bahrawy MA, Elishaev E, Erber R, Fereday S; AOCS Group; Fischer A, Gayther SA, Barquin-Garcia A, Gentry-Maharaj A, Gilks CB, Gronwald H, Grube M, Harnett PR, Harris HR, Hartkopf AD, Hartmann A, Hein A, Hendley J, Hernandez BY, Huang Y, Jakubowska A, Jimenez-Linan M, Jones ME, Kennedy CJ, Kluz T, Koziak JM, Lesnock J, Lester J, Lubiński J, Longacre TA, Lycke M, Mateoiu C, McCauley BM, McGuire V, Ney B, Olawaiye A, Orsulic S, Osorio A, Paz-Ares L, Ramón Y Cajal T, Rothstein JH, Ruebner M, Schoemaker MJ, Shah M, Sharma R, Sherman ME, Shvetsov YB, Singh N, Steed H, Storr SJ, Talhouk A, Traficante N, Wang C, Whittemore AS, Widschwendter M, Wilkens LR, Winham SJ, Benitez J, Berchuck A, Bowtell DD, Candido Dos Reis FJ, Campbell I, Cook LS, DeFazio A, Doherty JA, Fasching PA, Fortner RT, García MJ, Goodman MT, Goode EL, Gronwald J, Huntsman DG, Karlan BY, Kelemen LE, Kommoss S, Le ND, Martin SG, Menon U, Modugno F, Pharoah PDP, Schildkraut JM, Sieh W, Staebler A, Sundfeldt K, Swerdlow AJ, Ramus SJ, and Brenton JD. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. J Pathol Clin Res. (2023 Mar 22). doi: 10.1002/cjp2.311. Online ahead of print. PMID: 36948887.

Herzog C, Vavourakis CD, Barrett JE, Karbon G, Villunger A, Wang J, Sundström K, Dillner J, Widschwendter M. HPV-induced host epigenetic reprogramming is lost upon progression to high-grade cervical intraepithelial neoplasia. Int J Cancer. (2023 Feb 21). doi: 10.1002/ijc.34477. Online ahead of print. PMID: 36810770. 

Wang C, Block MS, Cunningham JM, Sherman ME, McCauley BM, Armasu SM, Vierkant RA, Traficante N; Australian Ovarian Cancer Study Group; Talhouk A, Ramus SJ, Pejovic N, Köbel M, Jorgensen BD, Garsed DW, Fereday S, Doherty JA, Ariyaratne D, Anglesio MS, Widschwendter M, Pejovic T, Bosquet JG, Bowtell DD, Winham SJ, Goode EL. Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma. Cancer Epidemiol Biomarkers Prev. (2023 Feb 15); OF1-OF8. doi: 10.1158/1055-9965.EPI-22-0941. PMID: 36790339.

Barrett JE, Jones A, Evans I, Herzog C, Reisel D, Olaitan A, Mould T, MacDonald N, Doufekas K, Newton C, Crosbie EJ, Bjørge L, Colombo N, Dostalek L, Costas L, Peremiquel-Trillas P, Ponce J, Matias-Guiu X, Zikan M, Cibula D, Wang J, Sundström K, Dillner J, Widschwendter M. The WID-EC test for the detection and risk prediction of endometrial cancer. Int J Cancer. (2022 Dec 19); doi: 10.1002/ijc.34406. Online ahead of print. PMID: 36533702.

Herzog C, Sundström K, Jones A, Evans I, Barrett JE, Wang J, Redl E, Schreiberhuber L, Costas L, Paytubi S, Dostalek L, Zikan M, Cibula D, Sroczynski G, Siebert U, Dillner J, Widschwendter M. DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN test. Clin Epigenetics. (2022 Nov 21); 14(1):150. doi: 10.1186/s13148-022-01353-0. PMID: 36414968.

Meagher NS, Hamilton P, Milne K, Thornton S, Harris B, Weir A, Alsop J, Bisinoto C, Brenton JD, Brooks-Wilson A, Chiu DS, Cushing-Haugen KL, Fereday S, Garsed DW, Gayther SA, Gentry-Maharaj A, Gilks B, Jimenez-Linan M, Kennedy CJ, Le ND, Piskorz AM, Riggan MJ, Shah M, Singh N, Talhouk A, Widschwendter M, Bowtell DDL, Candido Dos Reis FJ, Cook LS, Fortner RT, García MJ, Harris HR, Huntsman DG, Karnezis AN, Köbel M, Menon U, Pharoah PDP, Doherty JA, Anglesio MS, Pike MC, Pearce CL, Friedlander ML, DeFazio A, Nelson BH, Ramus SJ. Profiling the immune landscape in mucinous ovarian carcinoma. Gynecol Oncol. (2022 Nov 8); 168:23-31. doi: 10.1016/j.ygyno.2022.10.022. Online ahead of print. PMID: 36368129.

Weir A, Kang EY, Meagher NS, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Gentry-Maharaj A, Ryan A, Singh N, Widschwendter M, Alsop J, Anglesio MS, Beckmann MW, Berger J, Bisinotto C, Boros J, Brand AH, Brenton JD, Brooks-Wilson A, Carney ME, Cunningham JM, Cushing-Haugen KL, Cybulski C, Elishaev E, Erber R, Fereday S, Fischer A, Paz-Ares L, Gayarre J, Gilks BC, Grube M, Harnett PR, Harris HR, Hartmann A, Hein A, Hendley J, Hernandez BY, Heublein S, Huang Y, Huzarski T, Jakubowska A, Jimenez-Linan M, Kennedy CJ, Kommoss FKF, Koziak JM, Kraemer B, Le ND, Lesnock J, Lester J, Lubiński J, Menkiszak J, Ney B, Olawaiye A, Orsulic S, Osorio A, Robles-Díaz L, Ruebner M, Shah M, Sharma R, Shvetsov YB, Steed H, Talhouk A, Taylor SE, Traficante N, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Benitez J, Berchuck A, Bowtell DD, Candido Dos Reis FJ, Cook LS, DeFazio A; AOCs group, Doherty JA, Fasching PA, García MJ, Goode EL, Goodman MT, Gronwald J, Huntsman DG, Karlan BY, Kommoss S, Modugno F, Schildkraut JM, Sinn HP, Staebler A, Kelemen LE, Ford CE, Menon U, Pharoah PDP, Köbel M, Ramus SJ. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study. Br J Cancer. (2022 Nov 2); doi: 10.1038/s41416-022-02014-y. Online ahead of print. PMID: 36323878.

Barrett JE, Sundström K, Jones A, Evans I, Wang J, Herzog C, Dillner J, Widschwendter M. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer. Genome Med. (2022 Oct 19); 14(1):116. doi: 10.1186/s13073-022-01116-9. PMID: 36258199.

Lehtinen M, Pimenoff V, Nedjai B, Louvanto K, Verhoef L, Heideman D, El-Zein M, Widschwendter M, Dillner J. Assessing the risk of cervical neoplasia in the post-HPV vaccination era. International Journal of Cancer. (2022 Sep 12). doi: 10.1002/ijc.34286. Online ahead of print. PMID: 36093582.

Van der Kolk WL, Van der Zee AGJ, Slomovitz B, Baldwin P, Van Doorn HC, De Hullu JA, Van der Velden J, Gaarenstroom KN, Slangen BFM, Kjolhede P, Brännström M, Vergote I, Holland CM, Coleman R, Van Dorst EBL, Van Driel W, Nunns D, Widschwendter M, Nugent D, DiSilvestro PA, Mannel RS, Tjiong MY, Boll D, Cibula D, Covens A, Provencher D, Runnebaum IB, Monk B, Zanagnolo V , Tamussino K, Oonk MHM; all GROINSS-V I and II participants. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe. J Gynecol Oncol. (2022 Sep 6); S0090-8258(22)00489-9. doi: 10.1016/j.ygyno.2022.07.017. Online ahead of print. PMID: 36085090.

Schreiberhuber L, Herzog C, Vavourakis C, Redl E, Kastner C, Jones A, Evans I, Zikan M, Cibula D, Widschwendter P, Pfau K, Math B, Seewald M, Amory S, Obrist P and Widschwendter M. The WIDTM-qEC test – performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. International Journal of Cancer. (2022 Sep 2). doi: 10.1002/ijc.34275. Online ahead of print. PMID: 36056582.

Herzog C, Marín F, Jones A, Evans I, Reisel D, Redl E, Schreiberhuber L, Paytubi S, Pelegrina B, Carmona Á, Peremiquel-Trillas P, Frias-Gomez J, Pineda M, Brunet J, Ponce J, Matias-Guiu X, de Sanjosé S, Alemany L, Olaitan A, Wong M, Jurkovic D, Crosbie EJ, Rosenthal AN, Bjørge L, Zikan M, Dostalek L, Cibula D, Sundström K, Dillner J, Costas L, Widschwendter M. A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets. J Clin Oncol. (2022 Aug 24); JCO2200266. doi: 10.1200/JCO.22.00266. Online ahead of print. PMID: 36001862.

Bartlett TE, Evans I, Jones A, Barrett JE,  Haran S, Reisel D, Papaikonomou K, Jones L, Herzog C, Pashayan N, Simões BM, Clarke RB, Evans DG, Ghezelayagh TS, Ponandai-Srinivasan S, Boggavarapu NR,  Lalitkumar PG, Howell SJ, Risques RA, Flöter Rådestad A, Dubeau L, Gemzell-Danielsson K, Widschwendter M. Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. Genome Med. (2022 Jun 15); 14(1):64. doi: 10.1186/s13073-022-01063-5. PMID: 35701800.

Barrett JE, Herzog C, Kim Y-N, Bartlett TE, Jones A, Evans I, Cibula D, Zikan M, Bjørge L, Harbeck N, Colombo N, Howell SJ, Flöter Rådestad A, Gemzell-Danielsson K, Widschwendter M. Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock. Genome Biol. (2022 Feb 22); 23(1):52. doi: 10.1186/s13059-022-02603-3. PMID: 35189945.

Barrett JE, Herzog C, Jones A, Leavy OC, Evans I, Knapp S, Reisel D, Nazarenko T, Kim Y-N,  Franchi D, Ryan A, Franks J, Bjørge L, Zikan M, Cibula D, Harbeck N, Colombo N, Dudbridge F, Jones L, Sundström K, Dillner J, Flöter Rådestad A, Gemzell-Danielsson K, Pashayan N, Widschwendter M. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nat Commun. (2022 Feb 01); 13(1):449. doi: 10.1038/s41467-021-27918-w. PMID: 35105882.

Barrett JE, Jones A, Evans I, Reisel D, Herzog C, Chindera K, Kristiansen M, Leavy OC, Manchanda R, Bjørge L,  Zikan M, Cibula D, Widschwendter M. The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nature Commun. (2022 Feb 01); 13(1):448. doi: 10.1038/s41467-021-26615-y. PMID: 35105887.

Martinez RM, Müller H, Negru S, Ormenisan A, Mühr LSA, Zhang X, Møller FT, Clements MS, Kozlakidis Z, Pimenoff VN, Wilkowski B, Boeckhout M, Öhman H, Chong S, Holzinger A, Lehtinen M, van Veen E-B, Bała P, Widschwendter M, Dowling J, Törnroos J, Snyder MP, Dillner J. Human exposome assessment platform. Environ Epidemiol. (2021 Dec 3); 5(6):e182. doi: 10.1097/EE9.0000000000000182. eCollection 2021 Dec. PMID: 34909561.

Heinze K, Nazeran TM, Lee S, Krämer P, Cairns ES, Chiu DS, Leung SCY, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommoss F, Vollert H-W, Heitze F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, Kommoss FKF, Heublein S, Sinn H-P, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Tołoczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Gorringe KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon M, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PDP, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee C-H, Goode EL, Nelson BH, Ramus SJ, Kommoss S, Talhouk A, Köbel M, Anglesio MS. Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol. (2021 Dec 13); doi: 10.1002/path.5849. Online ahead of print. PMID: 34897700.

Oonk MHM, Slomovitz B, Baldwin PJW, van Doorn HC, van der Velden J, de Hullu JA, Gaarenstroom KN, Slangen BFM, Vergote I, Brännström M, van Dorst EBL, van Driel W, Hermans RH, Nunns D, Widschwendter M, Nugent D, Holland CM, Sharma A, DiSilvestro PA, Mannel R, Boll D, Cibula D, Covens A, Provencher D, Runnebaum I, Luesley D, Ellis P, Duncan TJ, Tjiong MY, Cruickshank DJ, Kjølhede P, Levenback CF, Bouda J, Kieser KE, Palle C, Spirtos NM, O’Malley DM, Leitao MM, Geller M, Dhar K, Asher V, Tamussino K, Tobias DH, Borgfeldt C, Lea JS, Bailey J, Lood M, Eyjolfsdottir B, Attard-Montalto S, Tewari K, Manchanda R, Jensen PT, Persson P, van Le L, Putter H, de Bock GH, Monk B, Creutzberg CL, van der Zee AGJ. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients with Micrometastases in the Sentinel Node: Results of GROINSS-V II. J Clin Oncol. (2021 Aug 25); JCO2100006. doi: 10.1200/JCO.21.00006. Epub 2021 Aug 25. PMID: 34432481.

Mühlberger N, Sroczynski G, Gogollari A, Jahn B, Pashayan N,Steyerberg E, Widschwendter M, Siebert U. Cost Effectiveness of Breast Cancer Screening and Prevention – A Systematic Review with a Focus on Risk-Adapted Strategies. Eur J Health Econ. (2021 Aug 3). doi: 10.1007/s10198-021-01338-5. Epub 2021 Aug 3. PMID: 34342797.

Kalsi JK, Ryan A, Gentry-Maharaj A, Margolin-Crump D, Singh N, Burnell M, Benjamin E, Apostolidou S, Habib M, Massingham S, Karpinskyj C, Woolas R, Widschwendter M, Fallowfield L, Campbell S, Skates S, McGuire A, Parmar M, Jacobs I, Menon U. Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar. Trials. (2021 Jan 25); 22(1):88. doi: 10.1186/s13063-020-04968-x. PMID: 33494753.

Kim  O, Young Park E, Young Kwon S, Shin S, Emerson RE, Shin Y-H, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, CheonD-J, Fernández FM, Nephew KP, Karpf AR, Widschwendter M, Sood AK, Bast Jr RC, Godwin AK, Miller KD, Cho C-H, Kim J. Targeting progesterone signaling prevents metastatic ovarian cancer. PNAS. (2020 Dec 15); 117(50):31993-32004. doi: 10.1073/pnas.2013595117. Epub 2020 Dec 1.PMID: 33262282.

Nené NR, Barrett J, Jones A, Evans I, Reisel D, Timms JF, Paprotka T, Leimbach A, Franchi D, Colombo N, Bjørge L, Zikan M, Cibula D, Widschwendter M. DNA methylation signatures to predict the cervicovaginal microbiome status. Clin Epigenetics. (2020 Nov 23); 12(1):180. doi: 10.1186/s13148-020-00966-7. PMID: 33228781.

Bolt I, Bunnik EM, Tromp K, Pashayan N,  Widschwendter M, de Beaufort I. Prevention in the age of personal responsibility: epigenetic risk-predictive screening for female cancers as a case study. J Med Ethics. (2020 Nov 18); 0:1–6. doi:10.1136/medethics-2020-106146. PMID: 33208479.

Sroczynski G, Gogollari A, Conrads-Frank A, Hallsson LR, Pashayan N, Widschwendter M, Siebert U. Cost-Effectiveness of Early Detection and Prevention Strategies for Endometrial Cancer-A Systematic Review. Cancers (Basel). (2020 Jul 11); 12(7):E1874. doi: 10.3390/cancers12071874. PMID: 32664613.

Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol. (2020 Jun 18); doi: 10.1038/s41571-020-0388-9. Online ahead of print. PMID: 32555420.

Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, Leong HS, Chen S, Intermaggio MP, Gilks B, Nazeran TM, Volchek M, Elatre W, Bentley RC, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, Leung S, Liu G, Johnson D, Chen B, Ovarian Cancer Study A, Alsop J, Banerjee S, Behrens S, Bodelon C, Brand AH, Brinton LA, Carney ME, Chiew YE, Cushing-Haugen KL, Cybulski C, Ennis D, Fereday S, Fortner RT, García-Donás J, Gentry-Maharaj A, Glasspool R, Goranova T, Greene CS, Haluska P, Harris HR, Hendley J, Hernandez BY, Herpel E, Jimenez-Linan M, Karpinskyj C, Kaufmann SH, Keeney G, Kennedy CJ, Köbel M, Koziak J, Larson MC, Lester J, Lewsley LA, Lissowska J, Lubiński J, Luk H, Macintyre G, Mahner S, McNeish IA, Menkiszak J, Nevins N, Osorio A, Oszurek O, Palacios J, Hinsley S, Pearce CL, Pike MC, Piskorz A, Ray-Coquard I, Rhenius V, Rodríguez-Antona C, Sharma R, Sherman ME, Silva D, Singh N, Sinn HP, Slamon DJ, Song H, Steed H, Stronach EA, Thompson PJ, Tołoczko-Grabarek A, Trabert B, Traficante N, Tseng CC, Widschwendter M, Wilkens LR, Winham SJ, Winterhoff BJ, Beeghly-Fadiel A, Benitez J, Berchuck A, Brenton JD, Brown R, Chang-Claude J, Chenevix-Trench G, DeFazio A, Fasching PA, Garcia MJ, Gayther SA, Goodman MT, Gronwald J, Henderson MJ, Karlan BY, Kelemen LE, Menon U, Orsulic S, Pharoah PDP, Wentzensen N, Wu AH, Shildkraut J, Rossing MA, Konecny GE, Huntsman DG, Huang RY, Goode EL, Ramus SJ, Doherty JA, Bowtell DDL, Anglesio MS. Development and Validation of the Gene-Expression Predictor of High-Grade-Serous Ovarian Carcinoma Molecular subTYPE (PrOTYPE). Clin Cancer Res. (2020 Jun 17); clincanres.0103.2020. doi: 10.1158/1078-0432.CCR-20-0103. Online ahead of print. PMID: 32554541.

Dilley J, Burnell M, Gentry-Maharaj A, Ryan A, Neophytou C, Apostolidou S, Karpinskyj C, Kalsi J, Mould T, Woolas R, Singh N, Widschwendter M, Fallowfield L, Campbell S, Skates SJ, McGuire A, Parmar M, Jacobs I, Menon U. Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. (2020 Jun 16); S0090-8258(20)31029-5. doi: 10.1016/j.ygyno.2020.05.002. Online ahead of print. PMID: 32561125.

Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, Chen S, Elatre W, Gilks B, Nazeran T, Volchek M, Bentley RC, Wang C, Chiu DS, Kommoss S, Leung SCY, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, George J, AOCS Group ,, Fereday S, Hendley J, Traficante N, Steed H, Koziak JM, Köbel M, McNeish IA, Goranova T, Ennis D, Macintyre G, Silva D, Ramón y Cajal T, García-Donas J, Polo SH, Rodriguez GC, Cushing-Haugen KL, Harris HR, Greene CS, Zelaya RA, Behrens S, Fortner RT, Sinn P, Herpel E, Lester J, Lubiński J, Oszurek O, Tołoczko A, Cybulski C, Menkiszak J, Pearce CL, Pike MC, Tseng C, Alsop J, Rhenius V, Song H, Jimenez-Linan M, Piskorz A, Gentry-Maharaj A, Karpinskyj C, Widschwendter M, Singh N, Kennedy CJ, Sharma R, Harnett PR, Gao B, Johnatty SE, Sayer R, Boros J, Winham SJ, Keeney GL, Kaufmann SH, Larson MC, Luk H, Hernandez BY, Thompson PJ, Wilkens LR, Carney ME, Trabert B, Lissowska J, Brinton L, Sherman ME, Bodelon C, Hinsley S, Lewsley LA, Glasspool R, Banerjee SN, Stronach EA, Haluska P, Ray-Coquard I, Mahner S, Winterhoff B, Slamon D, Levine DA, Kelemen LE, Benitez J, Chang-Claude J, Gronwald J, Wu AH, Menon U, Goodman MT, Schildkraut JM, Wentzensen N, Brown R, Berchuck A, Chenevix-Trench G, A. deFazio Gayther SA, García MJ, Henderson M, Rossing MA, Beeghly-Fadiel A, Fasching PA, Orsulic S, Karlan BY, Konecny GE, Huntsman DG, Bowtell DD, Brenton JD, Doherty JA, Pharoah PDP, Ramus SJ. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. (2020 May 27); S0923-7534(20)39841-0. doi: 10.1016/j.annonc.2020.05.019. Online ahead of print. PMID: 32473302.

Widschwendter M and Dubeau L. Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control. Cancers. (2020 Feb 27); 12(3). pii: E547. doi: 10.3390/cancers12030547. PMID: 32120796.

Sroczynski G, Gogollari1 A, Kuehne F, Hallsson LR, Widschwendter M, Pashayan N, Siebert U. A Systematic Review on Cost-Effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies. Cancer Prevention Research (Phila.). (2020 Feb 18); doi: 10.1158/1940-6207.CAPR-19-0506. [Epub ahead of print]. PMID: 32071120.

Nene NR, Reisel D, Leimbach A, Franchi D, Jones A, Evans I, Knapp S, Ghazali T, Timms JF, Paprotka T, Bjorge L, Zikan M, Cibula D, Colombo N, Widschwendter M. Association Between the Cervicovaginal Microbiome, BRCA1 Mutation Status, and Risk of Ovarian Cancer: A Case-Control Study. The Lancet Oncology. (2019 Aug); 20(8):1171-1182. doi: 10.1016/S1470-2045(19)30340-7. Epub 2019 Jul 9. PMID: 31300207.

Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, El-Bahrawy MA, Ness RB, Odunsi K, Steed H, Herpel E, Anglesio MS, Zhang B, Lambie N, Swerdlow AJ, Lubiński J, Vierkant RA, Goode EL, Menon U, Toloczko-Grabarek A, Oszurek O, Bilic S, Talhouk A, García-Closas M, Wang Q, Tan A, Farrell R, Kennedy CJ, Jimenez-Linan M, Sundfeldt K, Etter JL, Menkiszak J, Goodman MT, Klonowski P, Leung Y, Winham SJ, Moysich KB, Behrens S, Kluz T, Edwards RP, Gronwald J, Modugno F, Hernandez BY, Chow C, Kelemen LE, Keeney GL, Carney ME, Natanzon Y, Robertson G, Sharma R, Gayther SA, Alsop J, Luk H, Karpinskyj C, Campbell I, Sinn P, Gentry-Maharaj A, Coulson P, Chang-Claude J, Shah M, Widschwendter M, Tang K, Schoemaker MJ, Koziak JM, Cook LS, Brenton JD, Daley F, Kristjansdottir B, Mateoiu C, Larson MC, Harnett PR, Jung A, deFazio A, Gorringe KL, Pharoah PDP, Minoo P, Stewart C, Bathe OF, Gui X, Cohen P, Ramus SJ, Köbel M. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol. (2019 Dec); 32(12):1834-1846. doi: 10.1038/s41379-019-0302-0. Epub 2019 Jun 25. PMID: 31239549.

Rebitschek FG, Pashayan N, Widschwendter M, Wegwarth O. Do cancer risk and benefit-harm ratios influence women's consideration of risk-reducing mastectomy? A scenario-based experiment in five European countries. PLoS One. (2019 Jun 12); 14(6):e0218188. doi: 10.1371/journal.pone.0218188. eCollection 2019. PMID: 31188874.

Wegwarth O, Pashayan N, Widschwendter M, Rebitschek FG. Women's perception, attitudes, and intended behavior towards predictive epigenetic risk testing for female cancers in 5 European countries: a cross-sectional online survey. BMC Public Health. (2019 May 30); 19(1):667. doi: 10.1186/s12889-019-6994-8. PMID: 31146730.

Wegwarth O, Widschwendter M, Cibula D, Sundström K, Portuesi R, Lein I, Rebitschek FG, on behalf of the FORECEE (4C) Consortium. What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries. BMJ Open. (2018 Dec 28); 8(12):e023789. doi: 10.1136/bmjopen-2018-023789. PMID: 30593552. 

Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, Pharoah PD, Kommoss S, Jimenez-Linan M, Karlan BY, Gentry-Maharaj A, Menon U, Hernando Polo S, Candido Dos Reis FJ, Doherty JA, Gayther SA, Sharma R, Larson MC, Harnett PR, Hatfield E, de Andrade JM, Nelson GS, Steed H, Schildkraut JM, Carney ME, Høgdall E, Whittemore AS, Widschwendter M, Kennedy CJ, Wang F, Wang Q, Wang C, Armasu SM, Daley F, Coulson P, Jones ME, Anglesio MS, Chow C, deFazio A, García-Closas M, Brucker SY, Cybulski C, Harris HR, Hartkopf AD, Huzarski T, Jensen A, Lubiński J, Oszurek O, Benitez J, Fady M, Staebler A, Taran FA, Pasternak J, Talhouk A, Rossing MA, Hendley J; AOCS Group, Edwards RP, Fereday S, Modugno F, Ness RB, Sieh W, El-Bahrawy MA, Winham SJ, Lester J, Kjaer SK, Gronwald J, Sinn P, Fasching PA, Chang-Claude J, Moysich KB, Bowtell DD, Hernandez BY, Luk H, Behrens S, Shah M, Jung A, Ghatage P, Alsop J, Alsop K, García-Donas J, Thompson PJ, Swerdlow AJ, Karpinskyj C, Cazorla-Jiménez A, García MJ, Deen S, Wilkens LR, Palacios J, Berchuck A, Koziak JM, Brenton JD, Cook LS, Goode EL, Huntsman DG, Ramus SJ, Köbel M. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. J Pathol Clin Res. (2018 Oct); 4(4):250-261. doi: 10.1002/cjp2.109. Epub 2018 Sep 21. PMID: 30062862.

Lévesque E, Kirby E, Bolt I, Knoppers BM, de Beaufort I, Pashayan N, Widschwendter M. Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women's Cancer: Points to Consider. Public Health Genomics. (2018); 21(1-2):37-44. doi: 10.1159/000492663. Epub 2018 Sep 17. PMID: 30223261.

Austria T, Marion C, Yu V, Widschwendter M, Hinton DR, Dubeau L. Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways. Int J Cancer.  (2018 Dec 1); 143(11):2932-2942. doi: 10.1002/ijc.31659. Epub 2018 Oct 3. PMID: 29978915.

Alblas M, Velt KB, Pashayan N, Widschwendter M, Steyerberg EW, Vergouwe Y. Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review. Crit Rev Oncol Hematol. (2018 Jun); 126:92-99. doi: 10.1016/j.critrevonc.2018.03.023. Epub 2018 Mar 31. PMID: 29759571.

Zheng SC, Webster AP, Dong D, Feber A, Graham DG, Sullivan R, Jevons S, Lovat LB, Beck S, Widschwendter M, Teschendorff AE. A novel cell-type deconvolution algorithm reveals substantial contamination by immune cells in saliva, buccal and cervix. Epigenomics. (2018 Jul); 10(7):925-940. doi: 10.2217/epi-2018-0037. Epub 2018 Apr 25. PMID: 29693419.

Nunes N, Ambler G, Foo X, Widschwendter M, Jurkovic D. Prospective evaluation of IOTA logistic regression models LR1 and LR2 in comparison with subjective pattern recognition for diagnosis of ovarian cancer in an outpatient setting. Ultrasound Obstet Gynecol. (2018 Jun); 51(6):829-835. doi: 10.1002/uog.18918. Epub 2018 Jun 4. PMID: 28976616.

Gao Y, Widschwendter M, Teschendorff AE. DNA Methylation Patterns in Normal Tissue Correlate more Strongly with Breast Cancer Status than Copy-Number Variants. EBioMedicine. (2018 May); 31:243-252. doi: 10.1016/j.ebiom.2018.04.025. Epub 2018 May 4. PMID: 29735413.

Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundström K, Steyerberg EW, Vergouwe Y, Wegwarth O, Rebitschek FG, Siebert U, Sroczynski G, de Beaufort ID, Bolt I, Cibula D, Zikan M, Bjørge L, Colombo N, Harbeck N, Dudbridge F, Tasse AM, Knoppers BM, Joly Y, Teschendorff AE, Pashayan N; FORECEE (4C) Consortium. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nat Rev Clin Oncol. (2018 May); 15(5):292-309. doi: 10.1038/nrclinonc.2018.30. Epub 2018 Feb 27. Review. PMID: 29485132.

Lawn RB, Anderson EL, Suderman M, Simpkin AJ, Gaunt TR, Teschendorff AE, Widschwendter M, Hardy R, Kuh D, Relton CL, Howe LD. Psychosocial adversity and socioeconomic position during childhood and epigenetic age: analysis of two prospective cohort studies. Hum Mol Genet. (2018 Apr 1); 27(7):1301-1308. doi: 10.1093/hmg/ddy036. PMID: 29365106.

Widschwendter M, Evans I, Jones A, Ghazali S, Reisel D, Ryan A, Gentry-Maharaj A, Zikan M, Cibula D,  Eichner J, Alunni-Fabbroni M, Koch J, Janni WJ, Paprotka T, Wittenberger T, Menon U, Wahl B, Rack B, Lempiäinen H. Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Med. (2017 Dec 22); 9(1):115. doi: 10.1186/s13073-017-0499-9. PMID: 29268762.

Widschwendter M, Zikan Z, Wahl B, Lempiäinen H, Paprotka T, Evans I, Jones A, Ghazali S, Reisel D, Eichner J, Rujan T, Yang Z, Teschendorff AE, Ryan A, Cibula D, Menon U, Wittenberger T. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med.(2017 Dec 22); 9(1):116. doi: 10.1186/s13073-017-0500-7. PMID: 29268796.

Chen Y, Widschwendter M, Teschendorff AE. Systems-epigenomics inference of transcription factor activity implicates arylhydrocarbon-receptor inactivation as a key event in lung cancer development. Genome Biol.(2017 Dec 20); 18(1):236 DOI 10.1186/s13059-017-1366-0. PMID: 29262847.

Ong JS, Hwang LD, Cuellar-Partida G, Martin NG, Chenevix-Trench G, Quinn MCJ, Cornelis MC, Gharahkhani P, Webb PM, MacGregor S; Ovarian Cancer Association Consortium (Bowtell D, deFazio A, Gertig D, Green A, Parsons P, Hayward N, Whiteman D, Peuteman G, Van Brussel T, Smeets D, Gacucova L, Schurmann P, Kramer F, Zheng W, Park TW, Simon, Beer-Grondke K, Schmidt D, Windebank S, Hilker C, Vollenweider J, Paddock L, King M, Rodriguez-Rodriguez L, Samoila A, Bensman Y, Sherman M, Hutchinson A, Szeszenia-Dabrowska N, Peplonska B, Zatonski W, Soni A, Chao P, Stagner M, Luccarini C, Harrington P, Jacobs I, Widschwendter M, Wozniak E, Balogun N, Ryan A, Karpinskyj C, Ford J, Pye C, Amin Al Olama A, Dennis J, Dicks E, Michilaidou K, Kuchenbaker K, Ong JS, Hwang LD, Cuellar-Partida G, Bryne E, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Swerdlow AJ, Jones M, Orr N, Schoemaker M, Edwards DV, Brenton J, Benítez J, García MJ, Rodriguez-Antona C, Rossing MA, Fortner RT, Riboli E, Chang-Claude J, Eilber U, Wang-Gohrke S, Yannoukakos D, Goodman MT, Bogdanova N, Dörk T, Duerst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Heitz F, Karlan B, Olsson H, Kjaer SK, Jensen A, Giles GG, Bruinsma F, Hildebrandt MAT, Liang D, Wu X, Le Marchand L, Setiawan VW, Permuth JB, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Stampfer M, Willet W, Missmer S, Bjorge L, Kopperud RK, Bischof K, Vestrheim Thomsen LC, Kiemeney LA, Massuger LF, Pejovic T, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Gilks CB, Gronwald J, Jakubowska A, Lubiński J, Kluz T, Wentzensen N, Brinton L, Trabert B, Lissowska J, Høgdall E, Høgdall CK, Sandler DP, Wolk A, Tyrer JP, Song H, Eccles D, Campbell I, Glasspool R, McNeish I, Paul J, Siddiqui N, Sutphen R, McLaughlin JR, Phelan C, Anton-Culver H, Ziogas A, May T, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Wu AH, Huntsman D, deFazio A, Dansonka-Mieszkowska A, Kupryjanczyk J, Moes-Sosnowska J, Szafron LM, Cunningham JM, Winham SJ, Risch HA, Goode EL, Schildkraut JM, Pearce CL, Berchuck A, Pharoah PDP, Martin NG, Chenevix-Trench G, Quinn MCJ, Cornelis MC, Gharahkhani P, Webb PM, MacGregor S). Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol. (2017 Nov 25); 1-10. doi: 10.1093/ije/dyx236. [Epub ahead of print]. PMID: 29186515.

Simpkin AJ, Cooper R, Howe LD, Relton CL, Davey Smith G, Teschendorff AE, Widschwendter M, Wong A, Kuh D, Hardy R. Are objective measures of physical capability related to accelerated epigenetic age? Findings from a British birth cohort. BMJ Open. (2017 Nov 1); 7(10):e016708. doi: 10.1136/bmjopen-2017-016708. PMID: 29092899.

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Toloczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf AD, Ryan A, Chudecka-Glaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubinski J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Eilber U, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, deFazio A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido Dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. (2017 Dec 1); 3(12):e173290. doi: 10.1001/jamaoncol.2017.3290. PMID: 29049607.

Wang Y, Teschendorff AE, Widschwendter M, Wang S. Accounting for differential variability in detecting differentially methylated regions. Brief Bioinform. (2017 Aug 18); doi: 10.1093/bib/bbx097. [Epub ahead of print]. PMID: 29912290.

Tomar T, Alkema NG, Schreuder L, Meersma GJ, de Meyer T, van Criekinge W, Klip HG, Fiegl H, van Nieuwenhuysen E, Vergote I, Widschwendter M, Schuuring E, van der Zee AGJ, de Jong S, Wisman GBA. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Med. (2017 Jun 23); 15(1):116. doi: 10.1186/s12916-017-0870-0. PMID: 28641578.

Nunes N, Ambler G, Foo X, Naftalin J, Derdelis G, Widschwendter M, Jurkovic D. Comparison of two protocols for the management of asymptomatic postmenopausal women with adnexal tumours - a randomised controlled trial of RMI/RCOG vs Simple Rules. Br J Cancer. (2017 Feb 28); 116(5):584-591. doi: 10.1038/bjc.2017.17. Epub 2017 Feb 2. PMID: 28152542.

Wong M, Crnobrnja B, Liberale V, Dharmarajah K, Widschwendter M, Jurkovic D. The natural history of endometrial polyps. Hum. Reprod. (2017 Feb); 32(2):340-345. doi: 10.1093/humrep/dew307. PMID: 27994000.

Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, Prytomanova OM, Jacobs IJ, Widschwendter M, Menon U, Timms JF. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. Br J Cancer. (2017 Feb 14); 116(4):501-508. doi: 10.1038/bjc.2016.433. PMID: 28081538.

Milani A, Kristeleit R, McCormack M, Raja F, Luvero D, Widschwendter M, MacDonald N, Mould T, Olatain A, Hackshaw A, Ledermann JA. Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy. ESMO Open. (2017 Jan 31);1(6):e000117. doi: 10.1136/esmoopen-2016-000117. eCollection 2016. PMID:28848659.

Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, MacDonald N, Ledermann JA. Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. Gynecol Oncol. (2017 Jan); 144(1):57-60. doi: 10.1016/j.ygyno.2016.11.001.PMID: 27825669.

Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, Menon U, Schett G, Penninger JM. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget. (2017 Jan 17); 8(3):3811-3825. doi: 10.18632/oncotarget.14013.PMID: 28002811.

Yang Z, Wong A, Kuh D, Paul D, Rakyan VK, Leslie RD, Zheng SC, Widschwendter M, Beck S, Teschendorff AE. Correlation of an epigenetic mitotic clock with cancer risk. Genome Biol. (2016 Oct 3); 17(1):205. PMID: 27716309.

Kalwa M, Haenzelmann S, Otto S, Kuo C-C, Franzen J, Joussen S, Fernandez Rebollo E, Rath B, Koch C, Hofmann A, Lee S-H, Teschendorff A, Denecke B, Lin Q, Widschwendter M, Weinhold E, Costa I, Wagner W. The lncRNA HOTAIR Impacts on Mesenchymal Stem Cells via Triple Helix Formation. Nucl Acid Res. (2016 Sep 15); 44(22):10631-10643. PMID: 27634931.

Teschendorff AE, Zheng SC, Feber A, Yang Z, Beck S, Widschwendter M. The multi-omic landscape of transcription factor inactivation in cancer. Genome Med. (2016 Aug 25); 8(1):89. doi: 10.1186/s13073-016-0342-8. PMID: 27562343.

Levine ME, Lu AT, Chen BH, Hernandez DG, Singleton AB, Ferrucci L, Bandinelli S, Salfati E, Manson JE, Quach A, Kusters CDJ, Kuh D, Wong A, Teschendorff AE, Widschwendter M, Ritz BR, Absher D, Assimes T, Horvath S. Menopause Accelerates Biological Aging. Proc Natl Acad Sci USA. (2016 Aug 16); 113(33):9327-32. doi: 10.1073/pnas.1604558113. Epub 2016 Jul 25. PMID: 27457926.

Lemech CR, Ensell L, Paterson JC, Eminowicz G, Lowe H, Arora R, Arkenau HT, Widschwendter M, MacDonald N, Olaitan A, Mould T, Meyer T, Hartley J, Mitra A, Ledermann JA, McCormack M, Kristeleit RS. Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer. Oncology.(2016 Jun 3); 91(1):48-54. PMID: 27256106.

Doufekas K, Zheng SC, Ghazali S, Wong M, Mohamed Y, Jones A, Reisel D, Mould T, Olaitan A, Macdonald N, Teschendorff A, Widschwendter M. DNA methylation signatures in vaginal fluid samples for detection of cervical and endometrial cancer. Int J Gynecol Cancer. (2016 Jun 2). [Epub ahead of print]. PMID: 27258725.

Gao Y, Jones A, Fasching P, Ruebner M, Beckmann MW, Widschwendter M and Teschendorff A. The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. Clin Epigenetics. (2016 Jun 1); 8:63. eCollection 2016. PMID: 27257442.

Bartlett TE, Chindera K, McDermott J, Breeze C, Cooke WR, Jones A, Reisel D, Karegodar ST, Arora R, Beck S, Menon U, Dubeau L, Widschwendter M. Epigenetic reprogramming of Fallopian tube fimbriae in BRCA mutation carriers defines ovarian cancer evolution. Nature Communications. (2016 May 24); 7:11620. doi: 10.1038/ncomms11620. PMID: 27216078.

Lim A, Mesher D, Gentry-Maharaj A, Balogun N, Widschwendter M, Jacobs I, Sasieni P, Menon U. Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. BJOG. (2016 May); 123(6):1012-20. doi: 10.1111/1471-0528.13447. Epub 2015 May 29. PMID: 26032603.

Zheng SC, Widschwendter M, Teschendorff AE. Epigenetic drift, epigenetic clocks and cancer risk. Epigenomics. (2016 May); 8(5):705-19. doi: 10.2217/epi-2015-0017. PMID: 27104983.

Teschendorff AE, Jones A, Widschwendter M. Stochastic epigenetic outliers can define field defects in cancer. BMC Bioinformatics. (2016 Apr 22); 17:178. doi: 10.1186/s12859-016-1056-z. PMID: 27103033.

Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet. (2016 Mar 5); 387(10022):945-56. doi: 10.1016/S0140-6736(15)01224-6. Epub 2015 Dec 17. Erratum in: Lancet. 2016 Mar 5;387(10022):944. PMID: 26707054. 

Pashayan N, Reisel D, Widschwendter M. Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges. Pers Med. (2016 Mar 1); 13(2):93-95. PMID: 27053939.

Teschendorff AE Gao Y, Jones A, Ruebner M, Beckmann MW, Wachter DL, Fasching PA, Widschwendter M.DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nature Communications. (2016 Jan 29); 7:10478. doi: 10.1038/ncomms10478. PMID: 26823093.

Pharoah PDP, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K, AOCS Study Group Bogdanova N, Cicek MS, Cunningham JM, Fridley BL, Gentry-Maharaj A, Hillemanns P, Lele S, Lester J, McGuire V, Moysich KB, Poblete S, Sieh W, Sucheston-Campbell L, Widschwendter M, Ovarian Cancer Association Consortium, Whittemore AS, Dörk T, Menon U, Odunsi K, Goode EL, Karlan BY, Bowtell DD,Gayther SA, Ramus SJ. PPM1D mosaic truncating variants in ovarian cancer cases may be treatment related somatic mutations. Journal of the National Cancer Institute. (2016 Jan 27); 108(3). pii: djv347. doi: 10.1093/jnci/djv347. Print 2016 Mar. PMID: 26823519.

Paul DS, Jones A, Sellar RS, Mayor NP, Feber A, Webster AP, Afonso N, Sergeant R, Szydlo RM, Apperley JF, Widschwendter M, Mackinnon S, Marsh SGE, Madrigal JA, Rakyan VK, Peggs KS, Beck S. A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation. Genome Med. (2015 Dec) 7:128. DOI 10.1186/s13073-015-0246-z. PMID: 26669438.

Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EMJJ, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M. Intra-Gene DNA Methylation Variability is a Clinically Independent Prognostic Marker in Women's Cancers. PLoS One. (2015 Dec 2); 10(12):e0143178. doi: 10.1371/journal.pone.0143178. PMID: 26629914.

Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S, Vergote I, Calvert H, Jacobs IJ, Widschwendter M. HOTAIR And Its Surrogate DNA Methylation Signature Indicate Carboplatin Resistance In Ovarian Cancer. Genome Med. (2015 Oct 24); 7(1):108. doi: 10.1186/s13073-015-0233-4. PMID: 26497652.

Liu Y, Pike MC, Wu N, Lin YG, Mucowski S, Punj V, Tang Y, Yen HY, Stanczyk FZ, Enbom E, Austria T, Widschwendter M, Maxson R, Dubeau L. Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent. PLoS One. (2015 Oct 21); 10(10):e0139013. doi: 10.1371/journal.pone.0139013. PMID: 26488398.

Liu Y, Yen HY, Austria T, Pettersson J, Peti-Peterdi J, Maxson R, Widschwendter M, Dubeau L. A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.mutation carrier state. EBioMedicine. (2015 Sep 09); 2(10): 1318–1330. doi.org/10.1016/j.ebiom.2015.08.034. PMID: 26629527.

Widschwendter M, Burnell M, Fraser S, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Ping-Cheng Y, Evans DG, Jacobs IJ, Menon U, Wood CE, Dougall WC. Osteoprotegerin (OPG), the Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine. (2015 Sep 09); 2(10): 1331–1339. doi.org/10.1016/j.ebiom.2015.08.037. PMID: 26629528.

Yang Z, Jones A, Widschwendter M, Teschendorff AE. An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. Genome Biol. (2015 Jul 14); 16(1):140. doi: 10.1186/s13059-015-0699-9. PMID: 26169266.

Teschendorff AE, Yang Z, Wong A, Pipinikas CP, Jiao Y, Jones A, Anjum S, Hardy R, Salvesen HB, Thirlwell C, Janes SM, Kuh D, Widschwendter M. Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer. JAMA Oncol. (2015 Jul 1); 1(4):476-85. doi: 10.1001/jamaoncol.2015.1053. Erratum in: JAMA Oncol. 2015 Jul;1(4):544. PMID: 26181258.

Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol. (2015 Jun 20); 33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. Epub 2015 May 11. PMID: 25964255.

Del Rincón SV*, Widschwendter M*, Sun D, Ekholm-Reed S, Tat J, Teixeira LK, Ellederova Z, Grolieres E, Reed SI, Spruck C. Cks Overexpression Enhances Chemotherapeutic Efficacy by Overriding DNA Damage Checkpoints. Oncogene (2015 Apr 9); 34(15):1961-7. doi: 10.1038/onc.2014.137. Epub 2014 May 26. *equally contributed. PMID: 24858038. [IF: 7.357]

Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L; AOCS Study Group, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer. (2014 Dec 9); 111(12):2297-2307. doi: 10.1038/bjc.2014.567. Epub 2014 Oct 30. PMID: 25349970.

Nunes N, Ambler G, Foo X, Naftalin J, Widschwendter M, Jurkovic D. Use of IOTA Simple Rules for the diagnosis of ovarian cancer: a Meta-Analysis. Ultrasound Obstet Gynecol. (2014 Nov); 44(5):503-14. doi: 10.1002/uog.13437. Epub 2014 Oct 13. PMID: 24920435.

Asghar US, Imseeh G, Kirkwood AA, Widschwendter M, Olaitan A, Macdonald N, Mould T, McCormack M, Mitra A, Ledermann JA, Arora R, Kristeleit R. 930PA Retrospective Single Institution Study Evaluating Clinical Outcome and Prognostic Markers for Endometrial and Ovarian Carcinosarcomas (CS). Ann Oncol. (2014 Sep 1); 25(suppl_4):iv322. doi: 10.1093/annonc/mdu338.54.

Loddo M, Andryszkiewicz J, Rodriguez-Acebes S, Stoeber K, Jones A, Dafou D, Apostolidou S, Wollenschlaeger A, Widschwendter M, Sainsbury R, Tudzarova S, Williams GH. Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer. J Pathol. (2014 Aug); 233(4):344-56. doi: 10.1002/path.4393. PMID: 24931331.

Jiao Y, Widschwendter M, Teschendorff AE. A systems-level integrative framework for genome-wide DNA methylation and gene expression data identifies functional gene modules under epigenetic control. Bioinformatics (2014 Aug 15); 30(16):2360-6. doi: 10.1093/bioinformatics/btu316. Epub 2014 May 2. PMID: 24794928.

Teschendorff AE, Liu X, Caren H, Pollard SM, Beck S, Widschwendter M, Chen L. The Dynamics of DNA Methylation Covariation Patterns in Carcinogenesis. PLoS Comput Biol. (2014 Jul 10); 10(7): e1003709. doi: 10.1371/journal.pcbi.1003709. eCollection 2014. PMID: 25010556.

Anjum S, Fourkala E-O, Zikan M, Wong A, Gentry-Maharaj A, Jones A, Hardy R, Cibula D, Kuh D,  Jacobs IJ, Teschendorff AE, Menon U,  Widschwendter M. A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Med. (2014 Jun 27); 6(6):47. doi: 10.1186/gm567. eCollection 2014. PMID: 25067956.

Almouzni G, Altucci L, Amati B, Ashley N, Baulcombe D, Beaujean N, Bock C, Bongcam-Rudloff E, Bousquet J, Braun S, Paillerets BB, Bussemakers M, Clarke L, Conesa A, Estivill X, Fazeli A, Grgurević N, Gut I, Heijmans BT, Hermouet S, Houwing-Duistermaat J, Iacobucci I, Ilaš J, Kandimalla R, Krauss-Etschmann S, Lasko P, Lehmann S, Lindroth A, Majdič G, Marcotte E, Martinelli G, Martinet N, Meyer E, Miceli C, Mills K, Moreno-Villanueva M, Morvan G, Nickel D, Niesler B, Nowacki M, Nowak J, Ossowski S, Pelizzola M, Pochet R, Potočnik U, Radwanska M, Raes J, Rattray M, Robinson MD, Roelen B, Sauer S, Schinzer D, Slagboom E, Spector T, Stunnenberg HG, Tiligada E, Torres-Padilla ME, Tsonaka R, Soom AV, Vidaković M, Widschwendter M. Relationship between genome and epigenome - challenges and requirements for future research. BMC Genomics (2014 Jun 18); 15:487.  doi:10.1186/1471-2164-15-487. PMID: 24942464.

Wittenberger T, Sleigh S, Reisel D, Zikan M, Wahl B, Alunni-Fabbroni M, Jones A, Evans I, Koch J, Paprotka T, Lempiäinen H, Rujan T, Rack B, Cibula D, Widschwendter M. DNA methylation markers for early detection of women’s cancer: promise and challenges. Epigenomics (2014 Jun); 6(3):311-327. PMID: 25111485.

Tan Y, Sun D, Jiang W, Klotz-Noack K, Vashisht AV, Wohlschlegel J, Widschwendter M, Spruck C. PP2A-B55β Antagonizes Cyclin E1 Proteolysis and Promotes its Dysregulation in Cancer. Cancer Res. (2014 Apr 1); 74(7):2006-14. doi: 10.1158/0008-5472.CAN-13-1263. Epub 2014 Feb 7. PMID: 24509904. 

Hoivik EA, Kusonmano K, Halle MK, Berg A, Wik E, Werner HM, Petersen K, Oyan AM, Kalland KH, Krakstad C, Trovik J, Widschwendter M, Salvesen HB. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Oncotarget (2014 Feb 28); 5(4):1052-61. PMID: 24658009.

Jones A, Teschendorff AE, Li Q, Hayward JD, Kannan A, Mould T, West J, Zikan M, Cibula D, Fiegl H, Lee S-H, Wik E, Hadwin R, Arora R, Lemech C, Turunen H, Pakarinen P, Jacobs IJ, Salvesen HB, Bagchi MK, Bagchi IC, Widschwendter M. Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development. PLoS MED. (2013 Nov 12); 10(11): e1001551. PMID: 24265601.

Banerji CR, Miranda-Saavedra D, Severini S, Widschwendter M, Enver T, Zhou JX, Teschendorff AE. Cellular network entropy as the energy potential in Waddington’s differentiation landscape. Scientific Reports (2013 Oct 24); 3:3039. doi: 10.1038/srep03039. PMID: 24154593.

Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Intermaggio MP, Edlund CK, Ramus SJ, Gayther SA, Dubeau L, Fourkala EO, Zaikin A, Menon U, and Jacobs IJ. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. The Lancet Oncology 

(2013 Nov); 14(12): 1226–32. Published Online October 17, 2013. dx.doi.org/10.1016/S1470-2045(13)70448-0. PMID: 24140203.

Nunes N, Ambler G, Hoo WL, Naftalin J, Foo X, Widschwendter M, Jurkovic D. A Prospective Validation of the IOTA Logistic Regression Models (LR1 and LR2) in Comparison to Subjective Pattern Recognition for the Diagnosis of Ovarian Cancer. Int J Gynecol Cancer (2013 Nov); 23(9):1583-9. doi: 10.1097/IGC.0b013e3182a6171a. PMID: 24088790.

West J, Widschwendter M, Teschendorff AE. Distinctive topology of age-associated epigenetic drift in the human interactome. Proc Natl Acad Sci USA (2013 Aug 27); 110(35):14138-43. doi: 10.1073/pnas.1307242110.  Epub 2013 Aug 12. PMID: 23940324.

Bartlett TE, Zaikin A, Olhede SC, West J, Teschendorff AE, Widschwendter M. Corruption of the intra-gene DNA methylation architecture is a hallmark of cancer. PLoS One (2013 Jul 16); 8(7):e68285. doi: 10.1371/journal.pone.0068285. Print 2013. PMID: 23874574.

Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E, Magnusson K, Nilsson H, Malyukova A, Rantala J, Klevebring D, Viñals F, Bhaskaran N, Zakaria SM, Rahmanto AS, Grotegut S, Nielsen ML, Szigyarto CA, Sun D, Lerner M, Navani S, Widschwendter M, Uhlén M, Jirström K, Pontén F, Wohlschlegel J, Grandér D, Spruck C, Larsson LG, Sangfelt O. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med. (2013 Jul); 5(7):999-1018. doi: 10.1002/emmm.201202341. Epub 2013 Jun 14. PMID: 23776131.

Doufekas K, Hadwin R, Kandimalla R, Jones A, Mould T, Crowe S, Olaitan A, Macdonald N, Fiegl H, Wik E, Salvesen HB, Widschwendter M. GALR1 Methylation in Vaginal Swabs Is Highly Accurate in Identifying Women With Endometrial Cancer. Int J Gynecol Cancer (2013 Jul); 23(6): 1050-5. doi: 10.1097/IGC.0b013e3182959103. PMID: 23727823

Widschwendter M, Jones A, Teschendorff AE. Epigenetics makes its mark on women-specific cancers--an opportunity to redefine oncological approaches? Gynecol Oncol. (2013 Jan); 128(1):134-43. doi: 10.1016/j.ygyno.2012.09.027. Epub 2012 Oct 1. PMID: 23036354..

Nunes N, Foo X, Widschwendter M, Jurkovic D. A randomised controlled trial comparing surgical intervention rates between two protocols for the management of asymptomatic adnexal tumours in postmenopausal women. BMJ Open (2012 Dec 11); 2(6). doi:pii: e002248. 10.1136/bmjopen-2012-002248. Print 2012. PMID: 23233701.

Balogun N, Forbes A, Widschwendter M, Lanceley A. Noninvasive nutritional management of ovarian cancer patients: beyond intestinal obstruction. Int J Gynecol Cancer (2012 Jul); 22(6):1089-95. doi: 10.1097/IGC.0b013e318256e4d3. PMID: 22688964.

Teschendorff AE and Widschwendter M. Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics (2012 Jun 1); 28(11):1487-94. doi: 10.1093/bioinformatics/bts170. Epub 2012 Apr 6. PMID: 22492641.

Fourkala EO, Gentry-Maharaj A, Burnell M, Ryan, A, Manchanda R, Dawnay A, Jacobs I, Widschwendter M, Menon U. Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. British Journal of Cancer (2012 Jun 5); 106(12):1910-6. doi: 10.1038/bjc.2012.155. Epub 2012 May 17. PMID: 22596242.

Zhuang J, Widschwendter M, Teschendorff AE. A comparison of feature selection and classification methods in DNA methylation studies using the Illumina Infinium platform. BMC Bioinformatics (2012 Apr 24); 13:59. doi: 10.1186/1471-2105-13-59. PMID: 22524302.

Fourkala EO, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R, Soromani C, Hasenbrink G, Jacobs I, Dawnay A, Widschwendter M, Lichtenberg-Fraté H, Menon U. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocr Relat Cancer(2012 Apr 10); 19(2):137-47. doi: 10.1530/ERC-11-0310. Print 2012 Apr. PMID: 22199143.

Teschendorff AE, Jones A, Fiegl H, Sargent A, Zhuang J, Kitchener H & Widschwendter M. Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Medicine (2012 Mar 27); 4(3):24. PMID: 22453031.

Zhuang J, Jones A, Lee SH, Ng E, Fiegl H, Zikan M, Cibula D, Sargent A, Salvesen HB, Jacobs IJ, Kitchener HC, Teschendorff AE, Widschwendter M. The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women’s Cancer. PLoS Genet. (2012 Feb); 8(2):e1002517. doi: 10.1371/journal.pgen.1002517. Epub 2012 Feb 9. Erratum in: PLoS Genet. 2012 Mar;8(3). doi: 10.1371/annotation/35f168f3-c509-4b4f-b245-f6682325838e. PMID: 22346766.

Rosenthal AN, Heron G, Widschwendter M, Read S, Brunell C, Mould TA. Fooled by the film: delayed diagnosis of incarcerated small-bowel hernia after laparoscopic surgery for endometrial cancer. Int J Gynecol Cancer (2012 Feb); 22(2):337-9. doi: 10.1097/IGC.0b013e31823c244b. PMID: 22193712.

Liberal, V., Martinsson-Ahlzén, H., Liberal, J., Spruck, C., Widschwendter, M., McGowan, C., and Reed SI. Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins. Proc Natl Acad Sci USA (2012 Feb 21); 109(8):2754-9. doi: 10.1073/pnas.1102434108. Epub 2011 Jun 22. PMID: 21697511.

Goebel G, Berger R, Strasak M, Egle D, Mueller-Holzner E, Schmidt S, Rainer J, Presul E, Lang S, Jones A, Widschwendter M and Fiegl H. Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients. Brit J Cancer (2012 Jan 3); 106(1):189-98. PMID: 22108517.

Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, Daxenbichler G, Long T, Marth C, Laird-Offringa IA, Press MF, Dubeau L, Siegmund KD, Wu AH, Groshen S, Chandavarkar U, Roman LD, Berchuck A, Pearce CL, Laird PW. Genome-Scale Screen for DNA Methylation-Based Detection Markers for Ovarian Cancer. PLoS One (2011); 6(12):e28141. PMID: 22163280.

Koukoura O, Sifakis S, Soufla G, Zaravinos A, Apostolidou S, Jones A, Widschwendter M, Spandidos DA. Loss of imprinting and aberrant methylation of IGF2 in placentas from pregnancies complicated with fetal growth restriction. Int J Mol Med. (2011); 28(4):481-7. PMID: 21805044.

Teschendorff AE, Zhuang J, Widschwendter M. Independent Surrogate Variable Analysis as a tool to deconvolve confounding factors in large-scale microarray profiling studies. Bioinformatics (2011 Jun 1); 27(11):1496-505. PMID: 21471010.

Cibula D, Widschwendter M, Zikan M, Dusek L. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand. (2011); 90(6):559-63. PMID: 21355863.

Cibula D, Widschwendter M, Dušek L. Tubal Ligation and the Risk of Ovarian Cancer – review and meta-analysis. Hum Reprod Update (2011); 17(1): 55-67. PMID: 20634209.

Koukoura O, Sifakis S, Zaravinos A, Apostolidou S, Jones A, Hajiioannou J, Widschwendter M, Spandidos DA. Hypomethylation along with increased H19 expression in placentas from pregnancies complicated with fetal growth restriction. Placenta (2011); 32(1):51-7. PMID: 21129773.

Akhoondi S, Lindstrom L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grander D, Sangfelt O. Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res. (2010); 12(6):R105. PMID: 21122106.

Balogun N, Gentry-Maharaj A, Wozniak EL, Lim A, Ryan A, Ramus SJ, Ford J, Burnell M, Widschwendter M, Gessler SF, Gayther SA, Jacobs IJ, Menon U. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol. (2010); 64(5):525-30. PMID: 21074968.

Schramek D, Leibbrandt A, Sigl V, Kenner L, Hanada R, Joshi P,  Pospisilik JA, Lee H, Aliprantis A, Ormandy C, Glimcher L, Pasparakis M, Khoka R, Widschwendter M, Schett G, and Penninger JM. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010 Nov 4); 468(7320): 98-102. PMID: 20881962.

Goode E, Chenevix-Trench G, Song H, Ramus S , Notaridou M , Lawrenson K, Widschwendter M, et al., Ovarian Cancer Association Consortium. A Genome-Wide Association Study Identifies Susceptibility Loci for Ovarian Cancer at 2q31 and 8q24. Nat Genet. (2010 October); 42(10): 874–879. PMID: 20852632.

del Rincón S, Rogers J, Widschwendter M, Sun D, Sieburg HB, and Spruck C. Development and Validation of a Method for Profiling Post-Translational Modification Activities Using Protein Microarrays. PLoS One (2010 Jun 28); 5(6):e11332. doi: 10.1371/journal.pone.0011332. PMID: 20596523.

Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Muller-Holzner E, Jones A & Widschwendter M. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. (2010); 101: 1059-1066. PMID: 20156214.

Thirlwell C, Eymard M, Feber A, Teschendorff  A, Pearce K, Lechner M, Widschwendter M, Beck S. Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium Human Methylation27 BeadChip. Methods (2010); 52(3): 248-254. PMID: 20434562.

Fourkala EO, Hauser-Kronberger C, Apostolidou S, Burnell M, Jones A, Grall J, Reitsamer R, Fiegl H, Jacobs I, Menon U & Widschwendter M. DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery. Breast Cancer Res Treat. (2010); 120: 345-355. PMID: 19353266.

Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP, Savage DA, Mueller-Holzner E, Marth C, Kocjan G, Gayther SA, Jones A, Beck S, Wagner W, Laird PW, Jacobs IJ & Widschwendter M. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. (2010 Apr); 20(4): 440-446. PMID: 20219944.

Jones A, Lechner M, Fourkala EO, Kristeleit R, Widschwendter M. Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. Epigenomics (2010 Feb); 2(1):9-38. doi: 10.2217/epi.09.47. PMID: 22122746.

Widschwendter M, Apostolidou S, Jones AA, Fourkala EO, Arora R, Pearce CL, Frasco MA, Ayhan A, Zikan M, Cibula D, Iyibozkurt CA, Yavuz E, Hauser-Kronberger C, Dubeau L, Menon U & Jacobs IJ. HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. Int J Cancer (2009); 125: 2214-2218. PMID: 19621443.

Teschendorff AE. Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ & Widschwendter M. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One. (2009 dec); 4(12), e8274. PMID: 20019873.

Apostolidou S, Hadwin R, Burnell M, Jones A, Baff D, Pyndiah N, Mould T, Jacobs IJ, Beddows S, Kocjan G, Widschwendter M. DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer. (2009); 125:2995-3002. PMID: 19609949.

Widschwendter M, Lichtenberg-Frate H, Hasenbrink G, Schwarzer S, Dawnay A, Lam A, Menon U, Apostolidou S, Raum E, Stegmaier C, Jacobs IJ, Brenner H. Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. Br J Cancer. (2009); 101:160-5. PMID: 19491898.

Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ, Brenner H. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One (2008 Jul 16); 3(7):e2656. PMID: 18628976.

Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, Jones RL, Dowsett M, Mueller-Holzner E, Windbichler G, Daxenbichler G, Goebel G, Ensinger C, Jacobs I, Widschwendter M. Methylated NEUROD1 promoter is a marker for chemonsensitivity in breast cancer. Clin Cancer Res. (2008); 14: 3494-3502. PMID: 18519782.

Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ, Widschwendter M. HOXA11 DNA methylation – a novel prognostic biomarker in ovarian cancer. Int J Cancer. (2008); 123:725-729. PMID: 18478570.

Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. (2007 Oct 1); 67(19):9006-12. Erratum in: Cancer Res. (2008 Feb 15); 68(4):1245. Dofou, Dimitra [corrected to Dafou, Dimitra]. PMID: 17909001.

Lernen Sie mehr über das EUTOPS Institut


Martin Widschwendter ist Professor für Krebsprävention und -Screening und Direktor des European Translational Oncology Prevention and Screening (EUTOPS) Institutes.

Das Team

Finden Sie heraus, wer zu unserer Vision beiträgt.


Lernen Sie unsere Kooperationspartner kennen.


Lesen Sie unsere wissenschaftlichen Publikationen.


Wir sind immer an neuen talentierte Teammitglieder interessiert.